DANIEL KEMP

CEO
Shinobi Therapeutics, Inc.

Dr. Kemp is an accomplished researcher with over 30 publications who built his career at Novartis, Merck and Takeda over 20 years leading pipeline initiatives from early discovery through to the clinic. Prior to joining Shinobi, he was CEO of cell therapy company Wugen Inc, and previously was responsible for transacting Takeda's key strategic partnerships in the CAR-NK and CAR-T cell therapy space. Dr. Kemp received his BSc and Ph.D. in molecular pharmacology from the University of Kent at Canterbury, UK. He was awarded an HHMI Fellowship at Harvard Medical School and carried out his postdoc research on pancreatic beta-cell biology at Massachusetts General Hospital.